Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 1999

View Archived Issues

PPL Therapeutics overviews corporate restructuring, updates product pipeline

Orion reports interim results and progress

ImmunoGen options antibody from Duke and Johns Hopkins

DGT and Immunex renew IBD collaboration

Protein Design Labs highlights progress during 3rd quarter

Pharmacopeia and Otsuka enter drug discovery collaboration

Gemifloxacin active in vitro against anaerobes

Phase II trials initiated with MRE-0470 as CAD diagnostic

AVI BioPharma files IND with FDA for Resten-NG

Angiotech commences phase II clinical study of micellar paclitaxel in SPMS

Somatostatin receptor ligands synthesized and tested at Takeda

Pfizer's new 5-HT1 ligands useful for CNS and related disorders

Dihydropyrimidines for hepatitis B designed at Bayer

Wide series of GH-stimulating compounds presented by Novo Nordisk

Agents for Alzheimer's disease from Schering-Plough acting as muscarinic antagonists

New antibacterial agents from Bayer exert good activity against staphylococci

Celgene presents new TNF-alpha inhibitor and preliminary clinical results at AAPS meeting

Pharmacokinetic profiles of two oral AII antagonists described by Pfizer at AAPS

FDA requests confirmatory trial of Aldurazyme prior to BLA filing

Bosentan safe and effective in CHF during open-label extension of REACH-1

AAPS presentation for new beta3-adrenoceptor agonist: preclinical PK/PD of GW-0604

Pharmacokinetics of CP-331684 investigated in animal species

Tezosentan is safe and produces beneficial vasodilatory responses in patients with CHF

Detailed pharmacokinetics, pharmacodynamics and toxicokinetics reported for CI-1027

Ribozyme and Chiron initiate phase I/II studies of Angiozyme

Immune Response reports success with novel RA treatment approach

Entecavir: absorption, distribution, metabolism and excretion assessed in preclinical studies

FDA advisory panel recommends approval of Visudyne therapy for wet AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...